CVKD vs NSYS Comparison

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Nortech Systems Inc is a United States-based electronic manufacturing services company. It offers value-added engineering, technical, and manufacturing services and support, including project management, design, testing, prototyping, manufacturing, supply chain management, and post-market services. The company's manufacturing and engineering services include complete medical devices, printed circuit board assemblies, wire and cable assemblies, and complex higher-level electro-mechanical assemblies. It operates in the Medical, Aerospace, Defense, and Industrial markets, with key revenue coming from medical-related markets.